Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select

Articles

43
Show Summary
Show Bulletpoints
Detailed View
Slightly Bullish +25

Is ISRG's International Weakness a Temporary Drag or Structural Risk?

📉 Shares dropped 17.6% YTD despite strong procedure volumes globally.

🇨🇳 China faces structural headwinds from pricing pressure and local competition.

🇯🇵 Japan offers long-term growth potential as reimbursement outlook improves.

💰 Analysts forecast 2026 earnings to rise 15.7% year-over-year.

⚖ Stock trades at premium P/E with a "Hold" rating due to international uncertainty.

📉 ISRG's international revenue growth is mixed, with strong overall procedure volume but notable headwinds in China and Japan.

🇨🇳 In China, Intuitive Surgical faces structural challenges from slower tenders, pricing pressure, and increasing competition from domestic players.

🇯🇵 Japan presents cyclical challenges due to hospital capital constraints delaying adoption, though an improving reimbursement outlook supports a more constructive long-term view.

🌍 Outside of China and Japan, international markets are experiencing robust growth driven by expanding clinical adoption and training infrastructure.

⚖️ Analysts conclude that ISRG's international weakness is partly temporary (Japan) and partly structural (China), requiring strategic navigation of policy and competition.

📉 ISRG shares have declined 17.6% year-to-date, underperforming the industry average decline of 15%.

📊 The company trades at a forward P/E of 43.35, which is above the current industry average but below its five-year median of 70.45.

💰 Analysts expect Intuitive Surgical's 2026 earnings to rise approximately 15.7% compared to the prior year.

🏷️ The Zacks Rank for ISRG is #3 (Hold), reflecting the uncertainty surrounding its international market expansion.

🤔 Investors must determine if China will transition into a lower-margin, highly competitive market or if demand can offset margin pressure.

Bullish Signals
  • Outside US procedure growth remains strong.
  • Japan shows improving reimbursement and future demand.
  • Global demand outside China and Japan stays intact.
  • 2026 earnings expected to rise 15.7%.
  • Shares trade at 43.35 forward P/E, below 70.45 five-year median.
Risk Factors
  • China headwinds slow growth and impact system placements.
  • Domestic competition threatens margins amid China procurement volatility.
  • Hospital capital constraints delay Japan adoption and drag growth.
  • Valuation sits at a forward P/E of 43.35, signaling overvaluation.
  • Shares down 17.6% despite implied 2026 earnings growth.
Bullish Signals
  • Despite headwinds in China and Japan, Intuitive Surgical's overall Outside U.S. (OUS) procedure growth remains strong, demonstrating resilience in the core international segment.
  • In Japan, management highlighted an improving reimbursement environment that could gradually unlock demand and support future procedure growth, suggesting the local weakness is cyclical rather than structural.
  • Global demand fundamentals remain intact outside of China and Japan, supported by expanding clinical adoption, training infrastructure, and broader access to robotic-assisted surgery.
  • The Zacks Consensus Estimate for Intuitive Surgical's 2026 earnings implies a 15.7% rise from the year-ago period's level, indicating positive growth expectations.
  • Although shares have declined 17.6% so far this year, they are trading at a forward price-to-earnings ratio of 43.35, which is lower than its five-year median of 70.45, potentially presenting a valuation opportunity relative to history.
Risk Factors
  • Intuitive Surgical's China business faces significant headwinds including slower tender activity, intensified pricing pressure, and rising competition from domestic players, which is adversely impacting system placements and growth visibility.
  • The tender-based procurement system in China inherently introduces volatility, while a growing preference for local manufacturers complicates Intuitive Surgical's positioning and suggests the market may transition to lower margins.
  • Japan's international weakness stems from capital constraints within hospital systems that are delaying system adoption, creating cyclical but persistent near-term drag on growth.
  • Intuitive Surgical carries a Value Score of D and trades at a forward P/E of 43.35, which is above the industry average, indicating potential overvaluation relative to peers.
  • Shares of ISRG have lost 17.6% so far this year, significantly underperforming despite an implied earnings rise of 15.7% for 2026.
  • Zacks has assigned Intuitive Surgical a Rank #3 (Hold), signaling cautious sentiment compared to strong buy ratings available in the broader market.
Somewhat Bullish +50

Wall Street Analysts See a 25.06% Upside in Intuitive Surgical (ISRG): Can the Stock Really Move This High? - Eastern Progress

📈 ISRG shares rose 4% with analysts projecting a $589 short-term target (25.1% upside).

🆙 Positive earnings revisions boosted consensus estimates by 4.3%, reinforcing a Buy rating.

⚠️ Treat analyst price targets as directional guides rather than guaranteed guarantees.

📈 Intuitive Surgical (ISRG) shares closed at $470.99 after gaining 4% over the past four weeks.

🎯 Wall Street analysts calculate a mean short-term price target of $589, implying 25.1% upside potential from current levels.

📊 Analyst estimates range from a low of $440 (6.6% downside) to a high of $750 (59.2% upside).

⚖️ The standard deviation for analyst price targets is $63.45, indicating variability in the short-term consensus.

🛑 Research suggests that price targets often mislead investors due to business incentives between firms and analysts.

📉 Overly optimistic price targets may be set to promote coverage rather than reflect accurate valuations.

🤝 A tight clustering of price targets, like ISRG's standard deviation, signals strong analyst agreement despite potential bias.

📈 EPS estimate revisions have been predominantly positive, with 11 rising and only 1 falling in the last 30 days.

🆙 The Zacks Consensus Estimate for earnings has increased by 4.3% over the same period.

🏆 ISRG currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of nearly 4,000 ranked stocks based on earnings factors.

🔄 Historical data shows a strong correlation between positive earnings estimate revision trends and near-term stock price gains.

⚠️ Investors are cautioned not to rely solely on price targets but should view them as a guide rather than a guarantee.

🔭 The article concludes that while the magnitude of the gain is uncertain, the upward directional bias of targets is valid.

Bullish Signals
  • Shares of Intuitive Surgical (ISRG) gained 4% over the past four weeks, closing at $470.99.
  • Wall Street analysts indicate a mean short-term price target of $589, suggesting a potential upside of 25.1% from current levels.
  • The most optimistic analyst forecasts a 59.2% surge in the stock price to reach $750.00.
  • A tight clustering of price targets demonstrates strong agreement among analysts regarding the company's upward potential.
  • There has been increasing optimism among analysts about ISRG's earnings prospects, with the Zacks Consensus Estimate increasing 4.3%.
  • Eleven estimates have moved higher over the last 30 days while only one has gone lower.
  • ISRG holds a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks based on earnings estimate factors.
  • The company boasts an impressive externally-audited track record which supports conclusions about its near-term upside potential.
Risk Factors
  • Analyst consensus price targets have been historically unreliable, as empirical research indicates they mislead investors more often than they guide actual stock direction.
  • Many analysts set overly optimistic price targets to drum up interest in companies with which their own firms have business relationships or seek associations, potentially inflating the mean estimate of $589 for ISRG.
  • Despite a Zacks Rank #2 (Buy) status, the article notes that even high-probability picks have failure rates ('all our elite picks aren't winners'), and references past doubles like Hims & Hers Health as potential anomalies rather than guaranteed benchmarks.
  • The standard deviation among analyst estimates is $63.45, indicating significant variability in predictions, with the lowest estimate projecting a 6.6% decline from current levels, suggesting downside risk if sentiment shifts.
Bullish +75

Intuitive Surgical Inc (NASDAQ:ISRG) Screens as a Strong Growth Stock with a Promising Technical Breakout Setup - ChartMill

🚀 ISRG shows exceptional fundamentals with 25.92% EPS growth and zero debt.

⚖️ Price consolidates near resistance; a breakout could reverse the downtrend.

🛑 Set stop-losses below $453 to manage downside risk effectively.

📈 Intuitive Surgical (ISRG) combines fundamental strength with a promising technical setup, identified by a dual-discipline screening strategy.

💰 The company earned an 8/10 Growth rating, with EPS rising 25.92% and revenue expanding 20.51% over the past year.

🛡️ Financial health is exceptional, highlighted by a 9/10 ChartMill Health rating, zero outstanding debt, and a top-tier Altman-Z score of 40.00.

📊 Profitability remains robust with a 9/10 rating, allowing the firm to fund expansion without risky leverage while converting growth into earnings.

📉 Although the overall technical rating is low (1/10) due to negative long-term trends, the Setup Rating is solid at 8/10.

⚖️ Price has been consolidating between $448 and $491, currently hovering near a key resistance zone between $477.85 and $483.63.

🔁 A breakout above the resistance zone with strong volume could signal a reversal of the recent downtrend.

📈 A "Pocket Pivot" signal indicates volume-based accumulation by institutional buyers, reinforcing the potential for upward movement.

🛑 Investors can risk-manage the trade by setting stop-loss orders below the support zone around $453 to limit downside exposure.

🏥 Strong demand for the da Vinci and Ion surgical systems continues to drive the company's impressive top-line growth metrics.

📱 ChartMill lists ISRG in its fastest growing stocks screen due to high EPS and sales growth performance.

💹 ISRG is also featured on revenue growth leaders and High EPS Growth Stocks screens, confirming its status as a profitable health care leader.

⚠️ The analysis notes that even superior fundamentals are not a sufficient investment if the price or timing is incorrect.

🔍 This screening approach acts as a quality filter that specifically waits for favorable entry points based on technical configurations.

📜 All data and ratings are presented for informational purposes, with a disclaimer advising independent research or financial consultation.

Bullish Signals
  • Intuitive Surgical earned a Growth rating of 8 out of 10, with Earnings Per Share growing by 25.92% and revenue expanding by 20.51% over the past year.
  • The company carries no outstanding debt and achieved a ChartMill Health rating of 9 out of 10, supported by an Altman-Z score of 40.00 indicating near-zero risk of financial distress.
  • ISRG demonstrated strong profitability with a Profitability rating of 9 out of 10, effectively converting its rapid topline growth into real profits.
  • Technical analysis identifies a Setup Rating of 8 out of 10, suggesting the stock is consolidating near key resistance zones between $477.85 and $483.63 after trading in a range from roughly $448 to $491.
  • A recent 'Pocket Pivot' signal indicates that institutional buyers are stepping in to accumulate shares, adding weight to a potential price reversal.
  • The stock qualifies for multiple ChartMill screener lists including 'fastest growing stocks', 'revenue growth leaders', and 'High EPS Growth Stocks', highlighting its status as a market leader.
  • The risk/reward ratio is currently viewed as favorable, allowing investors to participate in a potential breakout while limiting downside by placing a stop-loss below the support zone around $453.
Risk Factors
  • The stock carries a poor overall technical rating of 1 out of 10 due to a negative long-term trend and 12-month underperformance relative to the broader market.
  • The company has been trading in a range between $448 and $491, hovering just below a key resistance zone which suggests limited upside potential until a decisive breakout occurs.
  • Despite a recent 'Pocket Pivot' signal, the setup relies on investors placing a stop-loss below the support zone around $453, which caps potential gains if the stock does not break out immediately.
  • The article warns that even strong fundamentals are insufficient if the stock is purchased at the wrong price or time, highlighting valuation risk as a major consideration.
Bullish +75

5 Revealing Analyst Questions From Intuitive Surgical’s Q1 Earnings Call - StockStory

📈 Q1 2026 results beat expectations with a 17% rise in total procedures.

⚙️ Utilization grew via after-hours work and new da Vinci 5 system adoption.

💰 Management faces questions on reimbursement impacts and AI clinical value integration.

📈 Intuitive Surgical reported Q1 2026 results that surpassed Wall Street expectations, driven by a 17% increase in total procedures.

🖤 CEO David Rosa attributed the strong performance to broad-based adoption of both da Vinci and Ion platforms globally.

⚙️ Utilization rates increased notably due to gains in after-hours procedures and uptake of newer systems like da Vinci 5 outside of urology.

🧠 Analyst Travis Steed from Bank of America questioned the role of AI, with management outlining plans for layered AI capabilities focused on clinical value via da Vinci 5's installed base.

💊 Larry Biegelsen of Wells Fargo sought specifics on appendectomy and Japan reimbursement, receiving a response that it is too early to quantify market impact but promising outcomes are emerging.

📉 CFO Jamie Samath noted that further utilization growth depends on regional mix and da Vinci 5 adoption, declining to provide a specific quantity for the opportunity.

🌍 Frederick Wise from Stifel asked why international instrument growth outpaced procedures, which was attributed to lumpy distributor ordering patterns and foreign exchange fluctuations.

🛠️ David Roman of Goldman Sachs inquired about SP platform adoption and international strategy, prompting management to outline continued investment in geographic clearances and a localized market access approach.

📊 Analysts expect future focus on the adoption pace of new products like Force Feedback instruments and the SP stapler.

💰 The company faces ongoing watch regarding the impact of new reimbursement policies and expanded indications in key international markets.

⚡ Key signposts for investors include sustaining innovation-led revenue growth and navigating input cost pressures.

📈 Intuitive Surgical's stock price rose from $451.29 to $472.05 following the earnings release.

📊 This summary covers analyst questions regarding AI, reimbursement, international strategy, and future adoption rates from the Q1 2026 earnings call.

🚀 The article also promotes StockStory's research report on whether ISRG is at an inflection point for buying or selling.

Bullish Signals
  • Intuitive Surgical's Q1 2026 results exceeded Wall Street expectations, driven by a 17% year-over-year increase in total procedures.
  • Management highlighted broad-based adoption across both the da Vinci and Ion platforms, with customers advancing minimally invasive care.
  • The company reported notable gains in after-hours and non-urology procedures, as well as increased uptake of newer systems like the da Vinci 5.
  • CEO David Rosa detailed plans for layered AI capabilities via da Vinci 5's installed base to drive clinical value and data-driven differentiation.
  • CFO Jamie Samath flagged promising early outcomes and incremental reimbursement opportunities for select procedures in Japan, despite being too early to quantify total impact.
  • Management outlined continued investment in geographic and procedural clearances internationally, along with a localized approach to market access and pricing.
Risk Factors
  • Management declined to quantify future procedure growth opportunities or system placement upside, leaving revenue visibility uncertain beyond current adoption trends.
  • International instrument and accessory growth outpaced procedures due to lumpy distributor ordering patterns and foreign exchange headwinds, raising questions about the sustainability of top-line velocity.
  • The pace of adoption for recently launched products, including Force Feedback instruments and the SP stapler, remains a critical signpost that has not yet been validated by strong metrics.
  • Management indicated it is too early to size market impacts or incremental reimbursement benefits for specific procedures like appendectomies in Japan, signaling significant timing uncertainty.
  • Company growth depends on navigating ongoing input cost pressures and sustaining innovation-led expansion without clear quantified reserves or margins disclosed.
Bullish +75

How Strong Q1 2026 Results and Completed Buyback Will Impact Intuitive Surgical (ISRG) Investors

📈 Q1 EPS beat consensus at $2.50 with revenue jumping 23% year-over-year.

🔧 Installed base grew to 431 units, driven by strong da Vinci 5 adoption.

⚠️ Analysts see upside despite valuation concerns and minor tariff headwinds.

📈 Intuitive Surgical (ISRG) reported Q1 2026 non-GAAP EPS of $2.50, beating the $2.11 analyst consensus.

💰 Revenue reached $2.77 billion, representing a 23% year-over-year increase driven by strong adoption of da Vinci systems.

🤖 The company placed 431 new da Vinci systems, including 232 units of the newer da Vinci 5 platform in its installed base.

📉 Shares are currently trading at a 20% discount to their 52-week high following a 15% decline over the last year.

🤲 Analysts recommend ISRG as a buying opportunity, with a price target of $615.93 implying roughly 28% upside.

🔍 da Vinci 5 utilization in the U.S. has grown by 4%, exceeding the performance metrics of the previous Xi generation.

🧬 Advanced procedure types like Single Port surgeries grew 68% year-over-year, bolstered by positive clinical studies.

⚠️ Bearish concerns focus on valuation multiples, with the stock trading at a P/E ratio of 58 and potential deceleration in growth.

🌍 External headwinds include tariffs on components from Mexico, Germany, and China adding approximately 1% revenue drag.

💊 The GLP-1 obesity drug trend has negatively impacted bariatrics procedures, causing a decline in that specific segment of 10%.

📉 Insider activity shows net selling, though analysts suggest this is largely attributable to scheduled stock vesting.

✅ Gross margins expanded to 67.8%, with da Vinci 5 contribution margins becoming comparable to the older Xi model.

🎯 A bull case scenario projects a total return of 34.6% if placements stay above 230 per quarter and tariffs remain stable.

📉 A bear case analysis suggests a lower price target of $546.67, which is still above the current stock price.

🔮 Long-term projections assume mid-teens procedure growth through 2030 alongside modest compression in valuation multiples.

💹 Continued buyback programs and high-quality compounder characteristics support the thesis despite recent volatility.

Bullish Signals
  • Intuitive Surgical delivered Q1 non-GAAP EPS of $2.50, beating the consensus estimate of $2.11 and marking four straight quarters of EPS beats.
  • Revenue surged 23% year-over-year to $2.77 billion, demonstrating robust demand despite market headwinds.
  • The company placed 431 da Vinci systems in the quarter, with 232 da Vinci 5 units now contributing to a growing installed base of 1,500 systems.
  • da Vinci 5 adoption is accelerating, driving U.S. utilization growth of 4%, which exceeds the performance of the legacy da Vinci Xi model.
  • Single Port procedures grew impressively by 68% year-over-year, while Ion procedures climbed 39%, bolstered by a Mayo Clinic study showing 79% diagnostic yield.
  • Gross margins expanded to 67.8%, and da Vinci 5 contribution margins have become comparable with the older Xi platform, indicating strong operating leverage.
  • Analysts see Intuitive Surgical trading at a 20% discount to its 52-week high, creating a potential buying opportunity with a price target of $615.93 implying 28% upside.
  • The stock has shown recent stabilization, gaining 2.77% over the past week following the strong Q1 earnings print on April 21.
Risk Factors
  • The stock is down 5.1% over the past year and trades 20% below its 52-week high, indicating recent bearish sentiment despite strong quarterly results.
  • Procedure growth is projected to decelerate from 18% in 2025 to between 13.5% and 15.5% in 2026, raising concerns about slowing top-line expansion.
  • Tariffs on sourcing from Mexico, Germany, and China are expected to add roughly 1% revenue drag, negatively impacting margins.
  • The adoption of GLP-1 medications has pulled bariatrics procedures down 10%, creating a specific headwind for that therapeutic area.
  • China faces policy-driven pricing pressure which could suppress revenue from that market.
  • Insider activity has shown net selling, although analysts attribute this largely to scheduled vesting rather than lack of confidence.
  • The setup weakens if procedure growth slips below 13% or if hospital capital expenditure tightens materially.
  • Future earnings projections are uncertain as international ramp-up for da Vinci 5 and telesurgery commercialization remain key variables.
Bullish +75

5 Stocks to Buy With Extensive Robotics Applications for 2026

🤖 Robotics sector shows strong potential driven by AI, automation, and market expansion.

⚠️ Investors face risks from high R&D costs, regulations, and data privacy issues.

📋 Zacks ranks five robotics stocks as "Buy," highlighting Autodesk and Intuitive Surgical.

🏭 Top firms like Rockwell expect double-digit revenue and earnings growth through 2026.

🤖 Robotics companies are driving efficiency in manufacturing, healthcare, and logistics, with the global market poised for significant growth fueled by AI and automation.

⚠️ Investors face risks in the robotics space, including high R&D costs, regulatory challenges, data privacy concerns, and societal impacts of automation.

📋 Zacks Investment Research recommends five robotics stocks with a "Buy" (Rank #2) rating for investment through 2026.

💻 Autodesk (ADSK) benefits from a cloud subscription model, strong cash flow, and AI-driven innovation across AutoCAD, Revit, and Fusion platforms.

📈 Autodesk is expected to grow revenue by 13% and earnings by 18.7% for the current year ending January 2027.

🏥 Intuitive Surgical (ISRG) is embedding AI into its robotic ecosystem via Case Insights, which provides objective performance metrics for surgeons.

📞 ISRG is piloting telecollaboration through Intuitive Telepresence to support remote surgical education and scaling digital features in healthcare.

💉 Intuitive Surgical expects revenue growth of 16.2% and earnings growth of 15.7% for the current year with improved analyst estimates.

🏭 Rockwell Automation (ROK) is focusing on productivity through automation investments across life sciences, food & beverage, mining, and other end markets.

📉 Recent acquisitions and portfolio optimizations at Rockwell are expected to drive growth despite manufacturing contraction and cost headwinds.

⚙️ Rockwell Automation anticipates revenue growth of 6% and earnings growth of 15.3% for the year ending September 2026.

🔬 Nordson (NDSN) is benefiting from steady demand in medical components and engineered fluid solutions, particularly in semiconductor electronics dispense.

📈 The Industrial Precision Solutions segment at Nordson has returned to modest organic growth as automotive and polymer processing demand stabilizes.

Bullish Signals
  • Intuitive Surgical is embedding AI and digital tools into its robotic ecosystem, with Case Insights integrated into da Vinci 5 providing objective performance indicators that link to improved clinical outcomes like reduced hospital stays.
  • ISRG is piloting Intuitive Telepresence for remote surgical support and education, positioning itself as a leader in broader AI-driven healthcare transformation.
  • The Zacks Consensus Estimate for ISRG's current year earnings has improved by 3.7% over the last seven days, signaling growing analyst confidence.
  • ISRG is expected to post revenue and earnings growth rates of 16.2% and 15.7%, respectively, for the current year.
  • Rockwell Automation is benefiting from investments across many end markets that will support growth despite cost headwinds, supply-chain issues, and a challenging contraction in manufacturing activity.
  • ROK's optimization efforts and price increase actions are expected to drive growth and negate negative market factors, while recent acquisitions will further boost performance.
  • Rockwell Automation is expected to deliver an earnings growth rate of 15.3% for the current year ending September 2026.
  • Nordson is seeing steady demand in medical components, with its Advanced Technology Solutions segment being lifted by strength in semiconductor-related electronics dispense and x-ray system product lines.
Risk Factors
  • The article explicitly warns that robotics technology is still evolving, posing inherent risks of high R&D costs with no guaranteed success.
  • Broader industry risks mentioned include regulatory challenges, market volatility, concerns about job displacement, and data privacy issues.
  • Intuitive Surgical's new AI features like Case Insights and Telepresence represent early-stage pilots that face potential delays or require additional regulatory adjustments before full commercial scaling.
  • Rockwell Automation must successfully navigate headwinds from elevated costs and a challenging contraction in manufacturing activity to realize its growth targets.
  • The article notes that only 0.1% of Rockwell Automation's earnings estimate improved over the last 30 days, suggesting relatively weak analyst momentum compared to peers.
  • Nordson's recent business performance is described as merely returning to 'modest organic growth,' implying a lack of significant upside momentum in key segments.
Bullish +75

5 Stocks to Buy With Extensive Robotics Applications for 2026

🤖 Five robotics stocks recommended for 2026 investment.

💰 All five hold a Zacks Rank #2 Buy rating.

📈 Includes Intuitive Surgical, Autodesk, and Rockwell Automation.

`.

2. **Analyze the Input Content:**

* Title: 5 Stocks to Buy With Extensive Robotics Applications for 2026.

* Source: Zacks Investment Research (via Globe and Mail).

* Date: Tue Apr 28, 8:26AM CDT.

* Topic: Robotics stocks for investment in 2026.

* Specific Company Mentioned: Intuitive Surgical Inc. ISRG is one of the five recommended stocks.

* Other Stocks: Autodesk (ADSK), Rockwell Automation (ROK), Nordson Corp (NDSN), Teradyne (TER).

* Zacks Rank: All picks carry a Zacks Rank #2 (Buy).

* Market

Bullish Signals
  • Intuitive Surgical Inc. ISRG recommended top robotics stock with Zacks Rank #2 (Buy).
  • Global robotics market poised for significant growth fueled by tech breakthroughs and AI.
  • Robotics companies drive efficiency and productivity across industries like manufacturing, healthcare and logistics.
Risk Factors
  • High R&D costs.
  • No guaranteed success.
  • Regulatory challenges.
  • Market volatility.
  • Job displacement.
  • Data privacy risks.
  • Tech evolution.
Bullish Signals
  • Intuitive Surgical Inc. ISRG is recommended as a top robotics stock with a Zacks Rank #2 (Buy).
  • The global robotics market is poised for significant growth fueled by technological breakthroughs and AI advancements.
  • Robotics companies drive efficiency and productivity across industries such as manufacturing, healthcare and logistics.
Risk Factors
  • Robotics companies face high research and development costs with no guaranteed success.
  • The sector faces regulatory challenges, market volatility, job displacement concerns, and data privacy risks.
  • Investment landscape uncertainty exists due to the evolving nature of robotics technology.
Bullish +75

3 Reasons Why Intuitive Surgical (ISRG) Is a Great Growth Stock - Yahoo Finance

📈 Intuitive Surgical ranked top growth stock with favorable Zacks Rank score.

💰 EPS projected to grow 12.4%, exceeding industry average of 10.6%.

💸 Year-over-year cash flow up 15.8%, surpassing peers at 0.8% growth.

📈 Annualized cash flow grew 19.5% over 3-5 years versus 6.9% industry.

📈 Intuitive Surgical (ISRG) is highlighted as a top growth stock by the Zacks Growth Style Score, featuring a favorable score and top Zacks Rank.

💰 The company's earnings per share (EPS) is projected to grow 12.4% this year, significantly outpacing the industry average of 10.6%.

📉 Historical EPS growth for ISRG stands at 13.8%, demonstrating a consistent track record of above-average profit expansion.

💸 Year-over-year cash flow growth is currently 15.8%, which surpasses both many peers and the industry average of 0.8%.

📈 The company's annualized cash flow growth rate has been 19.5% over the past 3-5 years compared to an industry average of 6.9%.

🔄 Upward revisions in earnings estimates have increased the Zacks Consensus Estimate by 0.6% over the past month.

✅ These positive financial trends support a Growth Score of B and solidify ISRG's status as a potential market outperformer for growth investors.

Bullish Signals
  • Intuitive Surgical holds a top Zacks Rank #2 and favorable Growth Score.
  • EPS expected to grow 12.4% this year, beating industry average of 10.6%.
  • Cash flow grew 15.8% YoY, vastly outperforming the industry average of 0.8%.
  • 3-5 year annualized cash flow growth reached 19.5%, versus 6.9% industry average.
  • Earnings estimates surged 0.6% in past month, showing strong positive momentum.
Risk Factors
  • Growth stocks carry above-average risk; betting on over-stories can cause large losses.
  • Intuitive Surgical has a Zacks Rank of 2, not top-tier Strong Buy status.
Bullish Signals
  • Intuitive Surgical has earned a favorable Growth Score and a top Zacks Rank, placing it on the list of cutting-edge growth stocks recommended by the proprietary system.
  • The company's EPS is expected to grow 12.4% this year, which crushes the industry average of 10.6%, indicating strong prospects for stock price gains.
  • Intuitive Surgical's year-over-year cash flow growth of 15.8% significantly outperforms the industry average of 0.8%, providing ample resources to fund new projects without raising expensive outside funds.
  • The company has achieved a historically superior annualized cash flow growth rate of 19.5% over the past 3-5 years compared to the industry average of 6.9%.
  • Positive momentum is evident with upward revisions in current-year earnings estimates, where the Zacks Consensus Estimate has surged 0.6% over the past month.
  • This combination of a Growth Score of B and a Zacks Rank #2 (Buy) indicates that Intuitive Surgical is a potential outperformer and a solid choice for growth investors.
Risk Factors
  • The article acknowledges that growth stocks usually carry above-average risk and volatility, noting that betting on a stock where the growth story is over could lead to significant loss.
  • Intuitive Surgical only carries a Zacks Rank of 2 (Buy) rather than a Zacks Rank #1 (Strong Buy), suggesting it may not be in the top tier of current recommendations despite its favorable Growth Score of B.
Very Bullish +76

ISRG Stock Price, Quote & Chart | INTUITIVE SURGICAL INC (NASDAQ:ISRG) - ChartMill

📉 ISRG stock fell 2.33% recently but gained 4.05% over the past month.

📈 Analysts rate fundamentals at 7/10 with a $615.86 price target, implying ~31% upside.

💎 Earnings beat estimates significantly with EPS growth of 14.43% forecasted for next year.

⚠ Technical analysis gives a low 1/10 rating due to underperformance this year.

🏢 Company specializes in robotic surgery systems and trades at a PE ratio of 48.96.

📉 Intuitive Surgical Inc. (ISRG) stock closed at $470.99, reflecting a 2.33% decline in the most recent trading session.

📈 Despite the daily drop, ISRG has gained 4.05% over the past month while declining 11.04% over the last year.

🚀 ChartMill identifies ISRG as part of several top-performing screens, including fastest growing stocks and revenue growth leaders.

⚠️ Technical analysis gives ISRG a low rating of 1 out of 10 due to its underperformance relative to the broader market this year.

💎 Fundamental analysis rates ISRG highly at 7 out of 10, reflecting its strong health and profitability within the healthcare industry.

📅 On April 20, 2026, the company reported earnings that beat analyst expectations by 16.77% for EPS and 3.89% for revenue.

🎯 With 41 analysts covering the stock, the consensus price target stands at $615.86, implying potential upside of roughly 30.76%.

📊 Analysts forecast an EPS growth of 14.43% and revenue growth of 15.78% for the upcoming year.

💹 The company currently trades at a price-to-earnings (PE) ratio of 48.96 based on non-GAAP earnings per share of $9.62.

📉 ISRG has not reported any dividend payments to shareholders, relying instead on capital appreciation and growth prospects.

🤖 The firm specializes in robotic-assisted surgical solutions, with its flagship da Vinci system used for various surgical specialties.

🔬 Intuitive Surgical also utilizes the Ion endoluminal system for minimally invasive diagnostics and lung biopsies.

🏢 Headquartered in Sunnyvale, California, the company employs 17,021 full-time staff and has been publicly listed since 2000.

⚠️ Investors should consult the Technical and Fundamental Analysis tabs for deeper insights into investment suitability.

💼 Full profile data is restricted to registered users who can view more detailed charts and competitor comparisons.

Bullish Signals
  • ISRG appears on multiple growth stock screens for revenue and upside potential.
  • April 20 EPS beat expectations by 16.77% with $2.50 reported earnings.
  • Revenue of $2.77B exceeded estimates by 3.89%.
  • Analysts target $615.86, suggesting 30.76% upside from current price.
  • Non-GAAP EPS grew 25.92% in the last twelve months to $9.62.
  • Future growth projected at 14.43% EPS and 15.78% revenue annually.
  • Company holds a fundamental score of 7 out of 10 for health and profitability.
  • ISRG employs 17,021 staff with da Vinci and Ion robotic systems.
Risk Factors
  • Stock down -2.33% today with short-term weakness.
  • No dividends paid to shareholders.
  • Technical rating of 1/10 vs 79.25% of peers performing better.
  • PE ratio at 48.96 may indicate overvaluation.
  • Stock down -11.04% over past year.
  • Analyst target implies 30.76% upside, which is aggressive.
Bullish Signals
  • ISRG is included in multiple ChartMill growth screens, including fastest growing stocks, revenue growth leaders, and highest analyst upside stock lists.
  • On April 20, 2026, ISRG beat EPS expectations by 16.77% and beat revenue expectations by 3.89% with reported EPS of $2.50 and revenue of $2.77 billion.
  • Analysts are projecting an average price target of $615.86 USD, implying a potential 30.76% upside from the current price of $470.99.
  • Over the last twelve months, non-GAAP EPS grew by 25.92% compared to the previous year with a trailing EPS of $9.62.
  • Analysts expect strong future growth with projected EPS growth of 14.43% and revenue growth of 15.78% for the coming year.
  • ISRG maintains an outstanding health and profitability rating in its fundamental assessment, scoring a 7 out of 10 on ChartMill fundamentals.
  • The company employs 17,021 full-time employees and operates a comprehensive ecosystem of robotic-assisted surgical solutions including the da Vinci and Ion systems.
Risk Factors
  • Today ISRG stock price decreased by -2.33%, showing short-term weakness despite longer-term gains.
  • The company has not paid a dividend to shareholders.
  • ChartMill assigns a low technical rating of 1 out of 10, indicating weak technical performance compared to the broader market where 79.25% of stocks are performing better.
  • The PE ratio stands at 48.96, which is relatively high and may be overvalued relative to earnings.
  • Over the past year, ISRG's stock price has decreased by -11.04%, demonstrating a notable annual decline despite appearing in multiple positive growth screens.
  • Analyst average price target of 615.86 USD implies a required 30.76% increase to reach targets, which is aggressive and may not materialize if market sentiment worsens.
Very Bullish +85

Intuitive Surgical Earnings Call Signals Robust Growth

📈 Q1 revenue rose 23% YoY to $2.77B, driven by strong global demand for robotic systems.

💰 Operating margin expanded to 39%, while non-GAAP net income jumped to $901 million.

⚠ Tariffs and cyber incident flagged as key risks affecting future margins and data security.

📈 Intuitive Surgical reported Q1 revenue of $2.77 billion, representing a 23% year-over-year increase driven by broad demand for robotic surgery systems.

💰 Recurring revenue reached $2.4 billion, accounting for 86% of total sales and reinforcing the company's high-visibility business model.

🚀 Total procedures climbed 17% year over year to 890,000, with Ion procedures surging 39% and da Vinci procedures rising 16%.

📉 International expansion is a key driver, with procedures outside the U.S. advancing 20% while U.S. volumes grew 15%.

🤖 Company installed 431 da Vinci systems in the quarter, including significant upgrades to da Vinci 5 platforms and increased trade-ins.

🔥 Utilization of newer da Vinci 5 systems is approximately 11% higher than the older Xi platform, boosting per-procedure revenue.

💵 Instruments and accessories revenue grew 23% to $1.7 billion, while I&A revenue per procedure increased to roughly $1,880.

📊 Non-GAAP operating margin reached 39%, and non-GAAP net income jumped to $901 million, outpacing revenue growth in earnings per share.

🌱 Single-Port procedures surged 68% year over year, supported by strong U.S. utilization of the SP system for various surgical needs.

⚕️ Mayo Clinic study data on Ion platform showed a diagnostic yield of 79% and significant increase in early-stage lung cancer diagnoses.

🇨🇳 China remains underperforming due to pricing policies and lack of reimbursement clarity, with no expected improvement until 2027.

🇯🇵 Japan procedure growth trailed historical norms following fewer system placements and potential financial constraints at public hospitals.

⚖️ U.S. da Vinci bariatric procedures declined about 10% due to the increased use of GLP-1 drugs for obesity management.

💻 The company disclosed a cyber incident leading to unauthorized access to some data, though operations remained unaffected.

⚠️ Management warned that tariffs and material costs will weigh on margins in the coming quarters, impacting future profitability growth.

🏦 Quarter-end cash and investments decreased to $8.0 billion due to share repurchases, strategic acquisitions, and capital spending.

👀 Executives remain cautious about potential healthcare policy shifts affecting patient behavior and procedure volumes in the future.

Bullish Signals
  • Revenue rose 23% YoY to $2.77B.
  • Recurring revenue reached $2.4B, up 23%, representing 86% of sales.
  • Total procedures climbed 17% YoY; da Vinci grew 16% to 847K units.
  • Ion procedures jumped 39% YoY to 43K systems.
  • Company placed 431 da Vinci systems, including 232 da Vinci 5 units.
  • Non-GAAP net income increased to $901M versus $662M prior year.
  • Single-Port procedures surged 68% YoY; U.S. system utilization up 22%.
  • Ion platform saw 39% growth with 79% diagnostic yield on lung cases.
  • Operating margin hit 39%; gross margin improved to 67.8%.
  • Cyber incident had no operational impact.
Risk Factors
  • China procedure growth lags due to low tenders, pricing pressures, and competition.
  • China regulatory clarity not expected until 2027, remaining a long-term drag.
  • Japan growth below norms from fewer system placements in 2025.
  • U.S. da Vinci bariatric procedures down ~10% from GLP-1 drug impact.
  • Cyber incident exposed customer/employee data despite containment efforts.
  • Higher freight, chip, oil, and tariff costs weigh on margins by year end.
  • Tariffs alone may cut gross margin ~100 basis points later in the year.
  • Health-care premium subsidy expiration risks negative patient behavior shifts.
Bullish Signals
  • Intuitive Surgical reported total revenue of $2.77 billion, representing a 23% year-over-year increase or 22% in constant currency.
  • Recurring revenue grew 23% to $2.4 billion and now accounts for 86% of total sales, reinforcing the company's high-visibility business model.
  • Total procedures climbed 17% year over year, with da Vinci procedures rising 16% to 847,000 and Ion procedures jumping 39% to 43,000.
  • The company placed 431 da Vinci systems in the quarter, including 232 da Vinci 5 systems, indicating strong platform adoption and upgrades.
  • Non-GAAP net income climbed to $901 million versus $662 million, while non-GAAP EPS rose to $2.50 from $1.81, showing earnings growth outpacing revenue.
  • Single-Port procedures surged 68% year over year, with U.S. SP system utilization up 22%, highlighting a fast-growing niche within the portfolio.
  • Ion procedure growth reached 39% as hospitals adopt the platform for lung procedures, supported by emerging clinical data showing a diagnostic yield of 79% and malignancy sensitivity of 85%.
  • Non-GAAP operating margin reached 39% with gross margin improving to 67.8%, demonstrating expanding profitability from scale benefits and pricing leverage.
  • Management disclosed that operations and products were not disrupted during the cyber incident, portraying the event as contained despite customer data notifications.
Risk Factors
  • China remains a significant weakness with procedure growth lagging the corporate average due to low tender activity, restrictive pricing policies, and intensifying domestic competition.
  • The company expects no clarity on provincial charge codes and reimbursement in China until 2027, which implies it will likely remain a drag relative to other regions for several years.
  • Japan's procedure growth trailed historical norms following fewer system placements in 2025, pointing to a thinner near-term capital pipeline despite new reimbursement policies taking effect in 2026.
  • U.S. da Vinci bariatric procedures declined about 10% due to increased use of GLP‑1 drugs for obesity management, presenting a structural challenge for this volume segment.
  • A cyber incident occurred in the quarter leading to unauthorized access to customer and employee data, adding a layer of non-financial risk that investors will monitor despite containment efforts.
  • Higher costs from freight, semiconductor memory, oil-related materials, and tariffs are set to weigh on margins later in the year, with updated guidance assuming about a 100-basis-point gross margin impact from tariffs alone.
  • Management remains cautious about potential health-care premium subsidies expiring and how resulting policy shifts could negatively influence patient behavior and procedure volumes over time.
Neutral 0

Intuitive Surgical: Forget The 40x P/E. Focus On The 10-Year Potential (Upgrade) - Seeking Alpha

🛑 Ignore the 40x P/E ratio; focus on long-term growth instead.

📈 Upgraded due to strong fundamentals persisting since 2024 coverage.

⚠️ Author holds no position and content is not financial advice.

🛑 The article title suggests a re-evaluation of Intuitive Surgical (ISRG) valuation, arguing against focusing solely on the 40x P/E ratio.

📈 The author advises investors to shift attention from current multiples to the company's long-term 10-year growth potential.

🆔 This is an upgrade recommendation based on the premise that ISRG retains strong fundamentals despite time passing since initial coverage in 2024.

⚠️ Standard disclosures state the author holds no stock position and has no plans to trade within 72 hours of writing.

📢 The content warns readers that past performance does not guarantee future results and is not financial advice.

Bullish Signals
  • The article recommends an upgrade for Intuitive Surgical (ISRG), suggesting that the current valuation metrics should not overshadow its long-term prospects.
  • The author emphasizes focusing on ISRG's potential over a 10-year horizon, indicating significant confidence in the company's future growth trajectory.
Risk Factors
  • Analyst's disclosure states they hold no position in Intuitive Surgical (ISRG) and have no plans to initiate such positions within the next 72 hours, indicating a lack of insider confidence at the current moment.
Very Bullish +80

Why Intuitive Surgical (ISRG) Stock Is Up Today - Yahoo Finance

🚀 ISRG beat Q2 2026 expectations with revenue up 23% to $2.77B.

💰 Adjusted EPS rose 18.7% and operating margin expanded to 38.4%.

⚠️ Stock dips recently due to geopolitical tensions, masking underlying strong fundamentals.

📈 Long-term holders still see a net gain of roughly 70% over five years.

📈 Intuitive Surgical (NASDAQ:ISRG) shares jumped 7.6% after reporting strong first-quarter 2026 financial results that significantly exceeded analyst expectations.

💰 The company reported revenue of $2.77 billion, representing a 23% year-over-year increase and surpassing forecasts by 5.8%.

📊 Adjusted earnings per share reached $2.50, which beat the consensus estimate by 18.7%, further reinforcing investor confidence.

🚀 Operating efficiency improved significantly as adjusted operating margin expanded to 38.4%, up 4.4 percentage points year-over-year.

📉 Despite the strong quarterly performance, ISRG shares are down 13.3% since the beginning of the year and trade 17.8% below their 52-week high.

⚠️ The recent stock drop was influenced by external factors including a 3.2% decline 26 days ago due to U.S.-Iran conflict uncertainty and policy deadline fears under the Trump administration.

🌍 Broader market concerns regarding prolonged conflicts and rising oil prices contributed to a slide in consumer confidence, reflected in a three-month low for the University of Michigan's sentiment index.

📈 Long-term value is highlighted as investors who bought $1,000 worth of shares five years ago would now see their investment worth approximately $1,700 despite recent declines.

📉 Stock volatility remains relatively low with only three moves greater than 5% over the last year, indicating today's gain was viewed as meaningful rather than fundamental.

Bullish Signals
  • Shares of Intuitive Surgical (ISRG) jumped 7.6% after reporting strong first-quarter 2026 financial results that significantly exceeded analyst expectations.
  • Revenue grew to $2.77 billion, representing a robust 23% year-over-year increase and surpassing forecasts by 5.8%.
  • Adjusted earnings of $2.50 per share comfortably beat the consensus estimate by 18.7%, demonstrating strong profitability.
  • Intuitive Surgical's adjusted operating margin expanded to 38.4%, a significant 4.4 percentage point increase year-on-year highlighting improved operational efficiency.
  • The company demonstrated top-line growth acceleration from its recent trends, reinforcing positive market sentiment.
  • Despite being down 13.3% year-to-date, the stock trades at $487.15 per share, offering upside potential toward its 52-week high of $592.85.
  • Investors who purchased shares five years ago would now see their investment appreciate from $1,000 to $1,700, reflecting long-term value growth.
Risk Factors
  • Intuitive Surgical shares have declined 13.3% year-to-date despite strong Q1 earnings, indicating underlying concerns or market weakness.
  • The stock is trading 17.8% below its 52-week high of $592.85 (recorded in January 2026), suggesting the current price fails to reach recent valuations.
  • Previous significant volatility was driven by geopolitical fears regarding the U.S.-Iran conflict and policy deadlines, which negatively impacted consumer confidence.
  • The University of Michigan's sentiment index slid to a three-month low due to escalation in oil prices and prolonged conflict concerns, creating macroeconomic headwinds.
  • Today's price move was partially attributed to broader market uncertainty rather than just Intuitive's performance, as shares dropped 3.2% recently when major indices fell.
Bullish +75

Intuitive Surgical's Selloff Sets Up a 30% Rebound Opportunity

📉 Stock down to ~$445 support level despite $2.77B Q1 revenue beat and institutional buying.

⚠ Risks include high valuation, competition from Medtronic, and slowing growth outlook.

🚀 30% upside potential to $600 target with strong device placements and AI catalysts.

📉 Intuitive Surgical faces headwinds from high valuation and slowing growth, though potential remains undervalued.

🤖 The company holds a first-mover advantage with over 12,000 robotic surgical devices installed and growing.

⚠️ Stock price has declined into April 2025 due to downward revisions but is supported by institutional accumulation.

📊 Analyst consensus targets suggest more than 30% upside from current support levels near $445 to $450.

💼 Institutional owners control over 80% of the stock and show strong buying activity through Q1 and Q2 2026.

🛡️ The balance sheet is net cash with cash more than 3.15 times total liabilities, offsetting buybacks.

💰 Q1 net revenue reached $2.77 billion, a 23.1% year-over-year increase beating consensus estimates by over 550 bps.

📈 Adjusted net income grew 36%, significantly outperforming top-line growth of roughly 17% in procedures.

🔧 Device placements increased by 12%, indicating sustained demand for the Da Vinci surgical system.

🛒 The company repurchased over $1.1 billion worth of shares in Q1 to reduce share count and improve leverage.

🎯 Technical indicators like MACD and stochastic suggest a trend-following move toward previous highs near $600.

⚠️ Primary risks include competition from Medtronic’s Hugo device and high valuation relative to earnings.

🌍 International expansion in Japan, where seven new robotic procedures were recently approved, is a major growth catalyst.

🤖 Success of the Da Vinci 5 system and AI opportunities are identified as key future drivers for stock performance.

💹 A full-year device growth guidance of approximately 14.5% has been reaffirmed by management.

Bullish Signals
  • Installed base exceeds 12,000 devices with strong market dominance.
  • Potential stock price increase of 50% supported by first-mover advantage.
  • Consistently outperforms analyst expectations in device deployments and volumes.
  • Institutional ownership exceeds 80% with accumulating activity in Q1-Q2 2026.
  • Q1 net revenue reached $2.77 billion, up 23.1% year-over-year.
  • Revenue beat consensus estimates by more than 550 basis points.
  • Installed base grew 12% in the latest quarter for continued gains.
  • Adjusted net income grew 36%, significantly outpacing revenue growth.
  • Full-year guidance forecasts Da Vinci device growth of approximately 14.5%.
  • Net cash position is 3.15 times total liabilities for robust balance sheet.
  • Executed over $1.1 billion in buybacks enhancing shareholder leverage.
Risk Factors
  • High valuation of 45X earnings and slowing growth pressure price since early 2025.
  • Stock trades at premium to target, risking downside if revenue forecasts prove inaccurate.
  • 80%+ institutional ownership creates significant simultaneous selling pressure risks.
  • Technical resistance near $560-$600 requires clearing $500 EMA for sustained upside.
  • Competition from Medtronic's Hugo device poses long-term risk in international markets.
  • International expansion depends on regulatory approvals creating geopolitical uncertainty.
  • Forward estimates 550 bps above actuals risk downside disappointment if execution falters.
  • Zero-debt balance sheet with net cash exposes interest rate and opportunity costs.
  • Q1 device placement growth of 17% projected to decelerate from 14.5% full-year guidance.
Bullish Signals
  • Intuitive Surgical's installed base exceeds 12,000 devices and continues to grow, demonstrating strong market dominance in robotic surgical procedures.
  • The company has a first-mover advantage that supports the potential for a stock price increase of 50% or greater over the next few years.
  • Intuitive Surgical consistently outperforms analyst expectations, with device deployments and procedure volumes continuing to grow.
  • Institutional ownership exceeds 80% of the stock, indicating strong conviction and accumulating activity throughout Q1 2026 and into Q2 2026.
  • Q1 net revenue reached $2.77 billion, representing a 23.1% year-over-year increase that outpaced consensus estimates by more than 550 basis points.
  • The installed base grew by 12% in the latest quarter, pointing to continued gains in upcoming quarters.
  • Adjusted net income grew by 36%, significantly outpacing revenue growth and demonstrating strong profitability improvement.
  • Full-year guidance forecasts Da Vinci device growth of approximately 14.5%, supported by strong performance in procedures and instruments sales.
  • Intuitive Surgical maintains a net cash position with cash holdings more than 3.15 times total liabilities, providing a robust balance sheet.
  • The company executed buybacks totaling over $1.1 billion in Q1, enhancing shareholder leverage while maintaining financial health.
  • Da Vinci 5 early success and international expansion opportunities, particularly in Japan's newly approved seven robotic procedures, serve as significant growth catalysts.
Risk Factors
  • Intuitive Surgical faces significant headwinds due to its high valuation of 45X current year earnings and slowing growth, which have weighed on price action since early 2025.
  • The stock is trading at a premium relative to its consensus price target, creating vulnerability if long-term revenue forecasts prove inaccurate despite consistent outperformance so far.
  • Institutional ownership concentration at over 80% creates potential selling pressure risks given that the bulk of institutional holders could exit simultaneously during market corrections.
  • Technical resistance levels remain challenging near $560 and $600, with a critical hurdle at the 150-day exponential moving average near $500 that must be cleared for sustained upside.
  • Competition from Medtronic's Hugo device poses a long-term risk, though currently limited to overseas markets, could intensify as competitors gain traction in international deployments.
  • International expansion relies heavily on regulatory approvals like the recent Japan approval of seven new robotic procedures, introducing geopolitical and regulatory uncertainty.
  • The company's reliance on forward estimates that are significantly higher than actuals (outpacing consensus by 550 bps) creates potential for downside disappointment if execution falters.
  • Zero-debt balance sheet while maintaining net cash exposes the company to interest rate risks and opportunity costs from not investing capital productively.
  • Q1 device placement growth of 17% is projected at full-year guidance of approximately 14.5%, suggesting potential deceleration in growth momentum over time.
Bullish +75

Why Intuitive Surgical (ISRG) Stock Is Up Today

📈 ISRG shares rose 7.6% after reporting Q2 revenue of $2.77B, beating estimates.

💵 Adjusted EPS reached $2.50, surpassing consensus by 18.7%.

🚀 Operating margin expanded to 38.4%, up 4.4 percentage points year-over-year.

⚠ Stock remains 17.8% below 52-week high despite strong quarterly performance.

📈 Intuitive Surgical (ISRG) shares rose 7.6% in the afternoon session after reporting strong first-quarter 2026 financial results that beat analyst expectations.

💵 The company reported revenue of $2.77 billion, a 23% increase year-over-year, surpassing forecasts by 5.8%.

📊 Adjusted earnings per share reached $2.50, exceeding the consensus estimate by 18.7%.

🚀 Operating margin expanded to 38.4%, up 4.4 percentage points from the prior year, reflecting improved profitability.

📉 Despite today's gain, ISRG has declined 13.3% year-to-date and trades 17.8% below its 52-week high of $592.85.

💼 The market considers this stock low volatility, having only three moves greater than 5% over the last year.

🌍 Previous stock drops were influenced by broader market declines due to U.S.-Iran conflict fears and policy uncertainty.

🛡️ Investors who purchased shares five years ago would see a $1,000 investment grow to approximately $1,700 today.

💡 Analysts view the margin expansion as evidence of operational efficiency resonating positively with investors.

⚠️ Market sentiment remains cautious regarding geopolitical risks despite the company's strong internal performance metrics.

Bullish Signals
  • Shares jumped 7.6% after strong Q1 2026 results.
  • Revenue hit $2.77B, up 23% and beating forecasts.
  • Adjusted EPS of $2.50 beat estimates by 18.7%.
  • Operating margin expanded 4.4 points to 38.4%.
  • 5-year investors see returns from $1,000 to $1,700.
Risk Factors
  • Stock down 13.3% YTD despite strong quarterly results.
  • Shares trade at $487.15, 17.8% below January 2026 high.
  • U.S.-Iran conflict and policy deadlines drove major indices lower.
  • Michigan sentiment index hit three-month low amid uncertainty.
  • Low volatility limits upside potential in deteriorating macro conditions.
  • Q1 2026 jump may be temporary, not fixing YTD decline.
Bullish Signals
  • Intuitive Surgical (NASDAQ:ISRG) shares jumped 7.6% in the afternoon session after reporting strong first-quarter 2026 financial results that significantly exceeded analyst expectations.
  • The company announced revenue of $2.77 billion, representing a 23% increase from the same period last year and surpassing forecasts by 5.8%.
  • Adjusted earnings of $2.50 per share comfortably beat the consensus estimate by 18.7%, demonstrating robust profitability.
  • Intuitive's adjusted operating margin expanded to 38.4%, a 4.4 percentage point increase year-on-year that highlights increased operational efficiency and resonated positively with investors.
  • Despite being trading 17.8% below its 52-week high of $592.85 from January 2026, investors who bought $1,000 worth of shares 5 years ago now hold an investment worth $1,700.
  • Intuitive Surgical's shares have not been very volatile with only 3 moves greater than 5% over the last year, suggesting stability in the business model.
Risk Factors
  • Despite strong quarterly results, Intuitive Surgical's stock remains down 13.3% year-to-date as of the latest trading session.
  • The stock is trading at $487.15 per share, which is 17.8% below its 52-week high of $592.85 reached in January 2026.
  • Recent market sentiment was negatively impacted by escalating uncertainty tied to the U.S.-Iran conflict and policy deadlines set by the Trump administration, causing major indices including the S&P 500 and Dow Jones Industrial Average to fall sharply.
  • The University of Michigan's sentiment index slid to a three-month low, indicating weakening consumer confidence that could affect broader market conditions for high-priced medical equipment like Intuitive Surgical's robotics.
  • Intuitive Surgical is categorized as not very volatile with only 3 moves greater than 5% over the last year, which may indicate slower potential upside compared to more dynamic growth stocks if the macro environment deteriorates further.
  • Today's 7.6% stock price jump occurred in an afternoon session after Q1 2026 results exceeded expectations, suggesting some investors may view this as a temporary reaction rather than a fundamental change that would correct the year-to-date decline.
Very Bullish +85

Why Robotic Surgery's Titan, Intuitive Surgical, Just Made A Bullish Move - Investor's Business Daily

📈 ISRG stock surged 7.2% after beating earnings and raising full-year guidance.

💰 Q1 sales hit $2.77B, with procedures growing 17% versus a 14.5% forecast.

🔧 da Vinci 5 adoption rose 11%, while Ion system procedures jumped 39%.

📈 Intuitive Surgical (ISRG) stock jumped 7.2% to close at $483.62 after beating first-quarter earnings expectations and raising its full-year outlook.

💰 Sales grew 23% year-over-year to $2.77 billion, significantly surpassing the Street's estimate of $2.62 billion.

📊 Adjusted earnings per share came in at $2.50, well above the consensus expectation of $2.12, representing a 38% increase from last year.

🔧 Procedures performed using the da Vinci and Ion robotic systems are projected to grow by 13.5% to 15.5% this year, revised up from prior guidance.

💉 Actual procedure growth in the first quarter reached 17%, exceeding analyst forecasts of 14.5%.

🤖 Utilization of the new da Vinci 5 system in the U.S. increased by 11% compared to its predecessor, now supporting emergency procedures like appendectomies.

🌍 International demand remains strong despite budget constraints and competition, particularly in Europe where the da Vinci 5 launch is expanding.

🔥 The Ion robotic system saw impressive 39% growth in procedures, specifically for lung biopsies.

📦 Intuitive Surgical placed 431 new da Vinci systems globally during the quarter, with a total installed base of over 11,000 units now active.

🛒 Revenue from new system placements rose approximately 24.5% to $651 million, while sales of instruments and accessories jumped 23% to $1.69 billion.

⚠️ Analysts noted minor headwinds including weakness in the Asian market, slightly lower-than-expected U.S. placements, and a slowdown in bariatric surgeries linked to weight-loss drug popularity.

👍 Both Leerink Partners and William Blair analysts maintain an "outperform" rating on the stock despite these minor challenges.

🎯 Leerink analyst Mike Kratky cut his price target from $622 to $573 to reflect broader sector valuation compression but remains bullish on the long-term outlook.

Bullish Signals
  • Intuitive Surgical (ISIR) sales grew 23% to $2.77 billion.
  • EPS reached $2.50, beating expectations of $2.12 by 38%.
  • Full-year procedure volume guidance raised to 13.5%-15.5% growth.
  • Q1 procedures surged 17%, exceeding the 14.5% expectation.
  • Da Vinci 5 utilization rose 11% with strong European demand.
  • Ion robotic systems saw a robust 39% procedure growth.
  • 431 Da Vinci systems placed, up 17% from prior year.
  • System placement revenue jumped 24.5% to $651 million.
  • Stock gained 7.2%, closing above 50-day moving average.
Risk Factors
  • Asia region faces pockets of weakness.
  • U.S. placements slightly lower than expected.
  • Global bariatric procedures slowed 10%.
  • International stocking orders down 10%.
  • Analyst cut target $622 to $573.
Bullish Signals
  • Intuitive Surgical beat first-quarter forecasts with sales growing 23% to $2.77 billion, surpassing analyst expectations of $2.62 billion.
  • Adjusted earnings per share reached $2.50, handily topping the Street's expectation of $2.12, representing a 38% increase in earnings.
  • The company raised its full-year outlook for procedure volume to between 13.5% and 15.5% growth, improving its prior guidance.
  • Procedures grew 17% in Q1, significantly exceeding the expectation of 14.5%, which drives demand for single-use tools and accessories.
  • The new da Vinci 5 system achieved 11% higher utilization than its predecessor, with strong international demand particularly in Europe.
  • Ion robotic surgery systems saw a robust 39% growth in procedures, indicating strong adoption for lung biopsies.
  • Intuitive Surgical placed 431 da Vinci systems, marking a 17% increase over the prior year period.
  • Revenue from system placements rose 24.5% to $651 million, while sales of instruments and accessories jumped 23% to $1.69 billion.
  • Stock jumped 7.2% on Wednesday, closing above its 50-day moving average for the first time since January.
Risk Factors
  • The company faces pockets of weakness in the Asia region.
  • U.S. system placements were slightly lower than expected.
  • There is a 10% slowdown in bariatric procedures globally.
  • International stocking orders experienced a 10% slowdown which could cloud the recent sales beat.
  • Leerink analyst Mike Kratky cut his price target from $622 to $573 due to compression in large-cap medtech sector valuations.
  • Analyst William Blair noted that the bariatric slowdown is potentially related to strong demand for weight-loss drugs, which could divert focus from surgical procedures.
Slightly Bullish +25

QQQ is up 1.3% today, on ISRG stock price movement - Quiver Quantitative

📈 QQQ jumped 1.3% as Intuitive Surgical surged 8.0%.

💼 ISRG insiders sold shares repeatedly with no recent buys.

✅ Analysts rate the stock highly with a $590 target.

📈 The QQQ ETF rose 1.3% today, driven primarily by an 8.0% surge in Intuitive Surgical (ISRG) stock prices.

💼 ISRG insiders have sold their shares 47 times over the past six months with no recorded purchases.

✅ Wall Street analysts have maintained a positive stance on ISRG, issuing only buy ratings and zero sell ratings recently.

🎯 A group of 15 analysts has provided price targets for ISRG, with a median target price set at $590.0.

📊 These data points regarding insider sales and analyst consensus are sourced from Quiver Quantitative dashboards.

⚠️ Readers are advised that the article contains financial disclaimers regarding potential ticker-mapping errors and lacks formal investment advice.

Bullish Signals
  • Intuitive Surgical (ISRG) stock is up 8.0% today, contributing to the broader QQQ ETF gaining 1.3%.
  • Wall Street sentiment remains strongly bullish with 3 firms issuing buy ratings and zero sell ratings on ISRG in recent months.
  • Analyst price targets indicate significant upside potential, with 15 analysts setting a median target of $590.00.
Risk Factors
  • ISRG insiders have sold shares 47 times over the past six months with zero purchases, indicating significant net selling activity that may signal a lack of internal confidence.
  • While Wall Street analysts currently hold buy ratings, the absence of any sell ratings limits visibility into potential downside risks or conflicting bearish viewpoints from other firms.
Very Bullish +85

How ISRG Just Secured The U.S. Market - Trefis

💰 Recurring revenue hit $2.4B, growing 23% to reach 86% of total mix.

🔨 da Vinci 5 secured the U.S. market with 85% of new system placements.

🌬️ Diagnostics diversified revenue streams, with Ion platform procedures surging 39%.

⚡ New tech boosts productivity, prompting a raised full-year growth guidance to 13.5–15.5%.

🔨 Intuitive Surgical (ISRG) established a structural "Platform Refresh Wall" in Q1 2026 with its da Vinci 5 system securing the U.S. market for the next decade.

💰 The company beat analyst estimates, posting $2.4 billion in recurring revenue which grew 23% year-over-year to reach 86% of the total revenue mix.

🤖 The da Vinci 5 accounted for 85% of all U.S. system placements in Q1 2026, significantly outpacing competitors like Medtronic's Hugo and Johnson & Johnson's Ottava.

⚡ Recurring revenue grew at a faster rate (23%) than the total installed base growth (12%), indicating that digital services and AI-driven training are compounding rapidly.

🛡️ High-margin recurring revenue provides a financial buffer against macro volatility, justifying the stock's premium valuation compared to traditional medical device peers.

🌬️ The Ion diagnostic platform achieved 39% procedure growth in Q1, demonstrating successful diversification into lung biopsies that mitigates exposure to bariatric volume declines.

📈 General surgery volumes, including cholecystectomy and hernia repair, now offset the slowdown in bariatric procedures, proving a diversified demand profile for the company.

🎯 Management raised full-year 2026 procedure growth guidance to a range between 13.5% and 15.5%, driven by higher utilization rates of the new system.

⚡ Early data shows that integrated digital architecture and Force Feedback technology improve productivity by reducing operative time and surgeon fatigue.

🌍 While U.S. dominance is secured, OUS markets still face competition from Medtronic's Hugo clinical data and Chinese domestic players like MicroPort.

⚠️ Management must manage expected short-term gross margin compression resulting from the initial manufacturing costs of ramping up dV5 production.

🏛️ The company maintains a total installed base of 11,395 systems as it refreshes hardware to maintain its global standard for infrastructure leaders.

💎 Trefis identifies ISRG as a High Quality Portfolio (HQ) strategy pick focusing on structural moats and high-integrity cash flows since inception.

Bullish Signals
  • Intuitive Surgical (ISRG) beat analyst estimates with $2.50 EPS and delivered 23% revenue growth in Q1 2026.
  • The da Vinci 5 system secured an 85% market share of U.S. system placements, effectively locking high-acuity hospitals into the ecosystem ahead of competitors like Medtronic and Johnson & Johnson.
  • Recurring revenue reached $2.4 billion in Q1 2026, representing a robust 23% growth rate that outpaced the 12% growth in the total installed base.
  • The Ion diagnostic platform recorded impressive 39% procedure growth in Q1, driven by successful diversification into lung biopsies and expansion in general surgery volumes.
  • Management raised full-year 2026 procedure growth guidance to a range of 13.5% to 15.5%, signaling strong confidence in future performance.
  • Early data indicates higher utilization rates for the new dV5 systems due to integrated digital architecture and Force Feedback technology, which improve productivity by reducing operative time.
Risk Factors
  • Although the da Vinci 5 (dV5) secures U.S. market share, ISRG must manage expected short-term gross margin compression resulting from the initial manufacturing costs of the dV5 production ramp.
  • Competitive threats persist as Medtronic's Hugo and Chinese domestic players like MicroPort are actively expanding in Outside United States markets with clinical data and domestic capabilities respectively.
  • The Ion diagnostic platform shows 39% procedure growth, but this success is being weighed against the broader procedural shift caused by the GLP-1 impact on bariatric volumes.
  • To maintain market dominance, ISRG must successfully execute a hardware refresh cycle across its total installed base of 11,395 systems to prevent competitors from establishing significant footholds over the next decade.
Bullish +75

Intuitive Surgical stock rises after Q1 beat (ISRG:NASDAQ) - Seeking Alpha

📈 Intuitive Surgical stock surged ~7%, marking its largest gain since October.

💰 Q1 revenue up 23% YoY and non-GAAP net income jumped 36% YoY.

⚡ Management raised the 2026 outlook after stronger-than-expected first quarter results.

📊 Citi and Jefferies reaffirmed Buy ratings following the positive earnings report.

⚖ Seeking Alpha kept a Hold rating due to valuation concerns relative to growth.

📈 Intuitive Surgical (ISRG) stock surged approximately 7%, potentially marking its largest intraday gain since October.

🏥 Q1 earnings and revenue both beat Wall Street consensus estimates as the company delivered strong financial performance.

💰 Revenue increased by roughly 23% year-over-year, while non-GAAP net income jumped by about 36% year-over-year.

🚀 Management raised its 2026 outlook following the better-than-expected first quarter results.

📊 Citi and Jefferies analysts reaffirmed their Buy ratings on the stock in response to the positive earnings report.

⚖️ Seeking Alpha maintained a Hold rating despite the gains, citing concerns about current valuation relative to growth potential.

Bullish Signals
  • Intuitive Surgical stock surged ~7% intraday, biggest gain since October.
  • Q1 revenue grew 23% YoY, surpassing analyst estimates.
  • Non-GAAP net income jumped 36% YoY, showing strong profitability.
  • Management raised 2026 outlook after positive Q1 results.
  • Citi and Jefferies reaffirmed Buy ratings on better-than-expected earnings.
  • Results show Intuitive Surgical's dominance in surgical robotics market.
Risk Factors
  • Seeking Alpha holds rating due to valuation concerns.
  • Not all analysts upgraded despite some Buy ratings.
Bullish Signals
  • Intuitive Surgical (ISRG) stock surged ~7% in intraday trading, potentially marking its biggest gain since October.
  • The company reported Q1 revenue growth of approximately 23% year-over-year, surpassing analyst consensus estimates.
  • Non-GAAP net income increased by roughly 36% year-over-year, reflecting strong profitability and operational performance.
  • Management raised its 2026 outlook after the positive Q1 results, signaling confidence in long-term growth prospects.
  • Major financial institutions including Citi and Jefferies reaffirmed their Buy ratings following the beat-and-raise event.
  • The better-than-expected earnings demonstrate Intuitive Surgical's continued dominance in the surgical robotics market.
Risk Factors
  • Seeking Alpha maintained a Hold rating despite positive analyst sentiment, citing specific concerns over the stock's valuation relative to its current growth trajectory.
  • The article highlights that not all Wall Street analysts upgraded Intuitive Surgical; Citi and Jefferies reaffirmed Buy ratings while Seeking Alpha kept its Hold due to valuation concerns.
Bullish +75

INTUITIVE SURGICAL ($ISRG) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative

✅ ISRG earnings beat estimates with $2.50 EPS and $2.77B revenue.

🚀 Stock rose 3.76% after-hours driven by positive Q1 results.

🔭 Analysts maintain buy ratings with a median target of $610.

📈 Intuitive Surgical (ISRG) reported Q1 2026 earnings of $2.50 per share, exceeding analyst estimates of $2.14 by $0.36.

💰 Revenue for the quarter reached $2.77 billion, surpassing the consensus estimate of $2.67 billion by approximately $104 million.

📊 Following the earnings release, the stock price rose 3.76% in after-hours trading on April 21st.

🔍 Insider trading data shows 47 sales and zero purchases of ISRG stock over the past six months.

🏛️ Congressional trading activity included four purchases and no sales of ISRG shares by members of Congress in the last six months.

📉 Institutional investor movement saw 1,235 investors adding shares while 859 decreased their positions in the most recent quarter.

🎖️ Over the last year, the company paid out $1.39 million in awards to its employees and leadership.

💡 Analyst sentiment remains positive with three firms issuing buy ratings and zero firms issuing sell ratings recently.

🎯 A group of 13 analysts have set a median price target of $610 for ISRG stock over the last six months.

📱 The article promotes Quiver Quantitative's various dashboards for tracking insider trading, hedge fund activity, and government contracts.

Bullish Signals
  • INTUITIVE SURGICAL reported Q1 2026 earnings of $2.50 per share, beating Wall Street estimates of $2.14 by $0.36.
  • The company's revenue reached $2.77 billion, surpassing analyst expectations of $2.67 billion.
  • Following the strong earnings release, INTUITIVE SURGICAL stock price gained +3.76% after market close.
  • Wall Street sentiment remains bullish, with 3 firms issuing buy ratings and zero sell ratings in recent months.
  • Analysts maintain a median price target of $610.0 for the stock, indicating continued upside potential.
  • Legislators show confidence in the company, as Members of Congress have purchased $ISRG shares 4 times with no sales over the past 6 months.
Risk Factors
  • Insiders have sold $ISRG stock 47 times in the past six months with zero purchases, indicating significant short-term selling pressure from company insiders.
  • Institutional investors decreased their positions by netting out to a decrease, as 859 investors reduced holdings while only 1,235 added shares during the most recent quarter.
Neutral 0

[8-K] INTUITIVE SURGICAL INC Reports Material Event - Stock Titan

🚫 The source website is currently unreachable due to a connection error.

⏱️ The server returned a timeout status indicating a network failure.

🔧 Try rebooting your router, modem, or checking firewall settings.

🔌 Verify proxy configurations if the issue persists on your system.

🔄 Reload the page after adjusting browser permissions and network tools.

🚫 The requested article content is inaccessible due to a connection error from the source website, www.stocktitan.net.

⏱️ The page returned an ERR_CONNECTION_TIMED_OUT status, indicating a network timeout issue.

🔧 Troubleshooting suggestions include checking cables, rebooting routers and modems, or refreshing browser firewall settings.

🔌 Users are advised to verify proxy server configurations in system network settings if the connection still fails.

🔄 Reloading the page may be necessary after adjusting firewall permissions for the Chromium browser.

Bullish Signals
  • The article references a filing from Intuitive Surgical (ISRG), indicating an active public market interest in the company's material events.
  • A new 8-K filing has been submitted, signaling that the company is proactively communicating important operational or strategic updates to investors.
Risk Factors
  • The source website (stocktitan.net) failed to load the SEC filing, indicated by an 'ERR_CONNECTION_TIMED_OUT' error and a timeout response.
  • Technical difficulties prevented immediate access to the full details of Intuitive Surgical's reported material event.